logo
Why Biden may not have known about his 'aggressive' prostate cancer until recently

Why Biden may not have known about his 'aggressive' prostate cancer until recently

Yahoo19-05-2025

Former President Joe Biden's office announced on Sunday that he was diagnosed with an "aggressive" form of prostate cancer.
Biden's office also said the cancer had metastasized, spreading to his bones.
Although some people were left wondering why the cancer was caught only after reaching a Gleason score of 9, oncology experts told ABC News that it's not uncommon for older prostate cancer patients to receive a diagnosis after the disease has advanced or spread.
MORE: What to know about prostate cancer after former President Joe Biden's diagnosis
"Prostate cancer is something that we always hope screening will identify early, when the cancer is all still inside the prostate," Dr. Alicia Morgans, a genitourinary medical oncologist at Dana-Farber Cancer Institute in Boston and a member of the board of directors of the no-profit Zero Prostate Cancer, told ABC News.
"Even if we screen everybody perfectly, there will never be 100% detection of prostate cancer because, in truth, cancer does not follow a rule book," Morgans continued. "And just because we are trying to catch it early doesn't mean it necessarily is present when we screen."
One screening test for prostate cancer involves a blood test that measures the level of prostate-specific antigens, which are proteins made by cells in the prostate gland.
Although there is no cutoff level that clearly indicates the presence of cancer, many doctors use a cutoff of 4 nanograms per milliliter to recommend further tests with a urologist, according to the American Cancer Society.
For an advanced form of cancer like Biden's, a recent PSA test would have likely shown elevated levels.
However, the U.S. Preventive Services Task Force recommends against PSA-based screening for men age 70 and older due to harms such as false positives leading to more tests or a diagnosis of problems that would not have caused symptoms or death.
MORE: Former President Joe Biden's cancer diagnosis: What does a Gleason score of 9 mean?
Morgans said it's unclear what the former president and his doctor discussed regarding screening, but it's plausible that he did not undergo PSA screening.
"It is absolutely possible that President Biden, like so many men over that age, have decided to stop doing PSA screening because they've decided that it is not consistent with their overall health goals and wishes, and that is completely reasonable," Morgans said.
Morgans said some men in their 70s and 80s do still undergo PSA screening for prostate cancer based on conversations with their primary care physicians and what's right for them.
Even so, it's possible that the results were normal -- either due to a false negative or because their cancer was not present at the time, she said.
"Prostate cancer can develop between screening tests," Morgans said. "It doesn't necessarily grow super slowly. It can develop between screenings, and it can be aggressive when it does develop; that doesn't mean it's not treatable."
Dr. Alan Bryce, chief clinical officer for City of Hope Cancer Center Phoenix, said there may be some patients who receive PSA screening results showing borderline-high results who decide not to pursue further testing.
"There are absolutely scenarios where that conversation happens with a patient or their family member," Bryce told ABC News. "All of them might say, 'You know what? Given where we're at in life, we're not that worried about this. Let's go ahead and wait another year.'"
MORE: 'Strongest in the broken places': Joe and Jill Biden say thanks amid cancer diagnosis
Bryce, a medical oncologist specializing in prostate and testicular cancers, added that shared decision-making is important when it comes to deciding if a patient wants to pursue prostate cancer screening -- and if they want to test further following test results that are abnormal.
"As physicians, we present patients with options and recommendations but, at the end of the day, it's still the patient's decision," he said. "So, it's entirely possible that a conversation happens and the patient decides they don't want to proceed with further workup. Maybe they don't want to do a scan, maybe they don't want to do a biopsy."
Advanced prostate cancer can present symptoms such as a weak urination stream; needing to urinate more often; erectile dysfunction; fatigue; weight loss; loss of bladder or bowel control; and pain in the ribs, hips and spine when the cancer had spread to the bones, according to the ACS.
Morgans said just because a patient has advanced prostate cancer, it doesn't necessarily mean that they will exhibit symptoms.
"I would say that it's more common than not that people sit in my office and tell me, 'You know, I don't have any symptoms. I don't understand how I have this cancer. I certainly don't understand how it could have spread outside of my prostate,'" Morgans said. "It is very common for people to be completely asymptomatic."
Bryce added that some symptoms, such as difficulty urinating or a weak urination stream, may be due to an enlarged prostate, which is common in older men.
"It is entirely normal that in older men, there is a degree of urinary obstruction that just happens with age," he said. "It's entirely possible that a man just has normal symptoms associated with aging and nothing about it stands out as being related to a cancerous process."
Why Biden may not have known about his 'aggressive' prostate cancer until recently originally appeared on abcnews.go.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

PeterMD Announces Official Website Update Featuring Telemedicine Services for Men's Hormone Health and TRT Support
PeterMD Announces Official Website Update Featuring Telemedicine Services for Men's Hormone Health and TRT Support

Yahoo

time23 minutes ago

  • Yahoo

PeterMD Announces Official Website Update Featuring Telemedicine Services for Men's Hormone Health and TRT Support

National Platform Offers Secure Access to Physician-Led TRT and Hormone Health Consultations from Anywhere in the U.S. VERO BEACH, June 10, 2025 (GLOBE NEWSWIRE) -- PeterMD, a Florida-based men's health telemedicine provider, has updated its official website to spotlight its nationwide services focused on testosterone replacement therapy (TRT), hormone optimization, and performance support. Available in all 50 states, PeterMD offers direct-to-consumer access to licensed providers via a secure digital platform. According to the official website ( PeterMD allows adult men to privately consult with certified TRT specialists, receive personalized treatment plans based on lab results, and manage therapy from the comfort of home. Services are available without insurance requirements, with fast turnaround times and HIPAA-compliant care. 'PeterMD was built to eliminate unnecessary barriers to men's health,' said a company spokesperson. 'We believe in transparent, physician-directed care that gives men control over their wellness without waiting rooms or stigma.' The telemedicine platform includes options for lab testing coordination, treatment supervision, and ongoing patient support. Every consultation is handled by a qualified medical professional trained in men's hormone health. Once a plan is approved, therapies are shipped directly with complete oversight from the PeterMD medical team. The updated site features secure registration, FAQs, and real-time access to specialists. New clients are invited to speak directly with a TRT specialist by calling or texting 772-800-6133. For existing patients, dedicated support is available at 772-444-8669 or via email at support@ PeterMD patient support hours: Monday–Sunday: 7 AM – 7 PM EST (for new inquiries) Monday–Friday: 9 AM – 5 PM EST (for existing patients) About PeterMD PeterMD is a telehealth provider based in Vero Beach, Florida, offering customized men's hormone and wellness solutions across the United States. The platform connects users with medical experts for private, fast, and clinically guided treatment—empowering men to reclaim their energy, focus, and vitality through modern, accessible care. Product and Contact Information Brand: PeterMDWebsite: support@ (New Patients): 772-800-6133Phone (Support): 772-444-8669Mailing Address: 601 21st Street, Suite 300, Vero Beach, FL, United StatesBusiness Hours:New Patients: Monday–Sunday, 7 AM – 7 PM ESTSupport: Monday–Friday, 9 AM – 5 PM EST Disclaimer This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. All medical decisions should be made in consultation with a licensed healthcare provider. Availability of telemedicine services may vary by state. PeterMD complies with all applicable healthcare regulations. CONTACT: Email: support@ Phone (New Patients): 772-800-6133 Phone (Support): 772-444-8669Sign in to access your portfolio

Toxic 'forever chemical' showing up in European food and wine
Toxic 'forever chemical' showing up in European food and wine

Yahoo

time2 hours ago

  • Yahoo

Toxic 'forever chemical' showing up in European food and wine

A team of researchers has found "alarmingly high" levels of trifluoroacetic acid (TFA), a so-called forever chemical, in dozens of organic and non-organic pastas, baked goods and breakfast cereals from Europe, as well as in wine. "In conventional grain products, the average levels were so high that a health risk to children can no longer be ruled out," said Helmut Burtscher-Schaden, an environmental chemist part of the Brussels-based Pesticide Action Network (PAN) Europe, which describes TFA as a "product of PFAS pesticides and industrial chemicals." Forever chemicals, also known as PFAS, are thousands of long-lasting substances used in household and everyday products since the middle of the 20th century but which have been found to be difficult to remove from the environment and from human bodies. The latest research points to 'widespread contamination from PFAS (per- and poly-fluoroalkyl substances) pesticides," PAN Europe said, warning that TFA tends to build up in water and farmland. The amount of TFA in the food items was found to be three times that recorded in a similar study eight years ago, according to PAN Europe, which in April warned of "dramatic rise" of TFA in wine. In a report covering wines from Austria, Belgium, Croatia, France, Germany, Greece, Hungary, Italy, Luxembourg and Spain, PAN Europe found that while pre-1988 vintages do not contain any such contamination, there has been a "sharp increase" in pesticide and chemical residues in wine bottled since 2010. Such a "steep accumulation" should be "a red flag that calls for decisive action," according to Michael Müller, a professor of pharmaceutical and medicinal chemistry at the University of Freiburg. The European Chemicals Agency has warned that TFA "may cause harm to the unborn child" and "may impair fertility."

NeuroSigma Announces Notice of Allowance for Patent Protecting Monarch eTNS System in China
NeuroSigma Announces Notice of Allowance for Patent Protecting Monarch eTNS System in China

Yahoo

time3 hours ago

  • Yahoo

NeuroSigma Announces Notice of Allowance for Patent Protecting Monarch eTNS System in China

LOS ANGELES, June 10, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing the Monarch external Trigeminal Nerve Stimulation (eTNS) device for treating attention-deficit hyperactivity disorder (ADHD), today announced a notice of allowance in China for a patent protecting the Monarch eTNS System. The patent, titled Pulse Generator for Trigeminal Nerve Stimulation, protects certain embodiments of NeuroSigma's core eTNS technology, including its second-generation Monarch device. The patent was allowed by China's National Intellectual Property Administration on May 27, 2025. In 2022, NeuroSigma licensed rights to the Monarch eTNS System for treating ADHD in China to Ignis Therapeutics, a leader in the development of novel therapeutics for central nervous system (CNS) conditions. 'As NeuroSigma continues to grow and work with our partners at Ignis, China will be a critical market for the Monarch eTNS System,' said Colin Kealey, M.D., President and CEO of NeuroSigma. 'This patent protects our second-generation Monarch device in China and significantly strengthens the company's intellectual property position.' "NeuroSigma's Monarch eTNS System is a highly innovative and effective therapy for ADHD,' added Tom Paschall, Director of NeuroSigma and CEO of Checkmate Capital. 'China is one of the largest and most important markets in the world for new CNS therapies. With this patent award, the Monarch device will benefit from robust intellectual property protection, which, we believe, will facilitate commercialization in this key market.' About NeuroSigma NeuroSigma is a Los Angeles, California-based bioelectronic medical device company developing technologies to transform medical practice and patients' lives. The company's lead product is the Monarch eTNS System, which is the first non-drug treatment for pediatric ADHD cleared by the FDA. Pipeline indications for the Monarch eTNS System include neurodevelopmental disorders such as autism spectrum disorder (ASD), learning disabilities, and epilepsy. NeuroSigma has received Breakthrough Device Designation for the Monarch eTNS System from the FDA in drug-resistant epilepsy. For more information about NeuroSigma, please visit For more information on the Monarch eTNS System, please visit Contact:Colin Kealey, M.D., President of NeuroSigma at CKealey@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store